MedDataX Logo

Silver Nanoparticles in Multidrug Resistant Bacteria

NCT ID: NCT04431440

Last Updated: 2020-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2020-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases. The present study investigated the bactericidal effect of AgNPs against Methecillin Resistant Staph. aureus (MRSA) and Vancomycin resistant Staph aureus (VRSA)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multidrug Resistent Bacteria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Methicillin resistant staphylococcus aureus

silver nanoparticles

Intervention Type OTHER

effect silver nanoparticles will be examined on multidrug resistant bacteria

vancomycin resistent staphylococcus aureus

silver nanoparticles

Intervention Type OTHER

effect silver nanoparticles will be examined on multidrug resistant bacteria

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

silver nanoparticles

effect silver nanoparticles will be examined on multidrug resistant bacteria

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Intensive care patients

Exclusion Criteria

* none
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rasha Hamed

lecturer of anaesthesia

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assiut university

Asyut, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Elsawy S, Elsherif WM, Hamed R. Effect of silver nanoparticles on vancomycin resistant Staphylococcus aureus infection in critically ill patients. Pathog Glob Health. 2021 Jul;115(5):315-324. doi: 10.1080/20477724.2021.1914412. Epub 2021 Apr 19.

Reference Type DERIVED
PMID: 33872131 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XXXXX

Identifier Type: -

Identifier Source: org_study_id